...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability.
【24h】

Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability.

机译:前列腺癌患者的直肠轮廓变异性:对直肠剂量-体积直方图和正常组织并发症发生率的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Recent investigations showed some correlation between three-dimensional (3D) treatment planning dose-volume data (dose-volume histograms: DVH, dose statistics) and rectal toxicity for patients treated for prostate cancer. However, no data are available about the possible impact of inter-institute variability in contouring the rectum, so that the possibility of reliably using information from single-centre studies remains doubtful. PURPOSE: Within a retrospective three-institutes study on correlation between dose-volume treatment planning data and rectum bleeding in patients treated for prostate cancer, an investigation about the impact of inter- and intra-observer variability in contouring the rectum was performed. MATERIALS AND METHODS: Ten patients were considered for a dummy run exercise and three observers (one per Institute) contoured the rectum (including filling). An anatomically based definition of rectum extension was previously accepted by the three observers. Six of the ten patients were randomly chosen in the subgroup of patients (large spacing, LS) with a distance between computed tomography (CT) slices (outside the prostate region) equal to 10 mm; for the remaining four patients the distance between CT slices was 5 mm over the whole rectum volume (small spacing, SS). The original 3D treatment planning was recovered on the Cadplan treatment planning system for each patient and rectum dose statistics (mean, median and maximum rectum dose), volume, DVH and NTCP values were calculated for each observer. For DVH analysis, the values of V(50), V(55), V(60), V(65) and V(70) (defined as the % of rectum volume receiving at least 50, 55, 60, 65, 70 Gy) were considered. Normal tissue complication probabilities (NTCPs) were calculated for the original ICRU dose and for a 75.6 Gy ICRU dose (NTCP and NTCP(75.6), respectively). Intra-observer variability was investigated by asking the observers to redraw the same rectum contours 6 months later and comparing the two contouring sessions. RESULTS: In general, a good agreement was found for most patients and, in particular, for all SS patients. The impact of inter-observer variability was quite significant on dose statistics and DVH in two of six LS patients. Looking at the patient population, some systematic deviations, even if quite small, were demonstrated between institute B and institute C (volume, P = 0.02) and between institute A and institute B (mean/median dose, V(50)-V(65), NTCP(75.6); P < 0.05). Four of six LS patients (0/4 in the SS group) presented a maximum difference among observers at the cranial and/or caudal limit of the rectum equal to 1 cm. For these patients, inter-observer variability was significantly higher than for the others (P < 0.03). When inter-observer variability was expressed in terms of standard deviations (SD), values around 2-3 Gy and 0.5 Gy for LS and SS patients, respectively, were found for mean/median dose; values around 3-4% and 0.5-2% for LS and SS patients, respectively, were found for V(50)-V(70). The average SD for NTCP and NTCP(75.6) were 0.4 and 0.6%, respectively (0.5 and 0.9% for LS patients; 0.2 and 0.3% for SS patients). Intra-observer variability was found to be lower than inter-observer variability even if the impact on dose statistics and DVH was visible. CONCLUSIONS: Once a robust definition of rectum is assessed, inter- and intra-institute variability in contouring the rectum appear relatively modest. However, the results suggest that the number of LS patients in DVH correlation studies should be as low as possible; the low number of these patients in the multi-centric trial involving our institutions should not have significant impact on the results of the study.
机译:背景:最近的研究表明,三维(3D)治疗计划的剂量-体积数据(剂量-体积直方图:DVH,剂量统计)与治疗前列腺癌的患者的直肠毒性之间存在一定的相关性。但是,目前尚无关于机构间变异性可能对直肠轮廓造成影响的数据,因此可靠地使用来自单中心研究的信息的可能性仍然值得怀疑。目的:在一项针对前列腺癌患者的剂量-体积治疗计划数据与直肠出血之间的相关性的回顾性三机构研究中,对观察者间和观察者间差异对直肠轮廓的影响进行了调查。材料与方法:10名患者被考虑进行假跑锻炼,三名观察员(每个研究所一名)对直肠进行了轮廓勾画(包括充盈)。三位观察者先前都接受了基于解剖学的直肠扩展定义。十个病人中有六个被随机选入病人亚组(大间距,LS)中,计算机断层摄影(CT)切片(前列腺区域外)之间的距离等于10mm;对于其余四名患者,CT切片之间的距离在整个直肠体积内为5 mm(小间距,SS)。在Cadplan治疗计划系统上为每个患者恢复了原始3D治疗计划,并为每个观察者计算了直肠剂量统计信息(平均,中位数和最大直肠剂量),体积,DVH和NTCP值。对于DVH分析,V(50),V(55),V(60),V(65)和V(70)的值(定义为接受至少50、55、60、65, 70 Gy)。计算原始ICRU剂量和75.6 Gy ICRU剂量(分别为NTCP和NTCP(75.6))的正常组织并发症概率(NTCP)。通过要求观察者在6个月后重新绘制相同的直肠轮廓并比较两个轮廓绘制时段,来观察观察者内部的变异性。结果:一般而言,对于大多数患者,尤其是所有SS患者,发现了良好的共识。六名LS患者中有两人的观察者间差异对剂量统计和DVH的影响非常显着。从患者人群的角度来看,在机构B和机构C之间(即使体积很小,P = 0.02)以及在机构A和机构B之间(均值/中位数剂量,V(50)-V( 65),NTCP(75.6); P <0.05)。六名LS患者中的四名(SS组为0/4)在直肠的颅骨和/或尾巴极限等于1 cm时出现观察者之间的最大差异。对于这些患者,观察者间的差异显着高于其他患者(P <0.03)。当观察者间的差异以标准差(SD)表示时,对于LS和SS患者,平均/中位剂量分别约为2-3 Gy和0.5 Gy。 LS和SS患者的V(50)-V(70)值分别约为3-4%和0.5-2%。 NTCP和NTCP(75.6)的平均SD分别为0.4和0.6%(LS患者为0.5和0.9%; SS患者为0.2和0.3%)。发现观察者内部的变异性低于观察者之间的变异性,即使对剂量统计和DVH的影响可见。结论:一旦评估了一个可靠的直肠定义,在直肠轮廓上的机构间和机构内变异性就显得相对适中。但是,结果表明,在DVH相关性研究中,LS患者的数量应尽可能少。在涉及我们机构的多中心试验中,这些患者人数很少,应该不会对研究结果产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号